Correlation of ICSBP expression with pretreatment risk groups and cytogenetic response to IFN-α in CML patients.

(A) The ICSBP level of samples without IFN treatment was analyzed (total n = 72). Twenty-four samples were divided into different risk groups by Sokal score: low risk (n = 10; below 0.8), intermediate risk (n = 4; 0.8-1.2) and high risk (n = 10; above 1.2). The data revealed a correlation of low ICSBP level with high risk (low versus high P = .007; low versus intermediateP = .374; intermediate versus high P = 0.188; Mann-Whitney test). (B) The ICSBP level of samples under IFN-α was analyzed (total n = 55). Forty-two samples were divided in groups of “good” (CR/PR; n = 27) and “poor” (MinR/NR; n = 15) responders and revealed a significant difference in ICSBP expression (P = .0002, Mann-Whitney test).